In vitro Antiviral Activity of Recombinant Antibodies of IgG and IgA Isotypes to Hemagglutinin of the Influenza A Virus

Abstract

⎯Seasonal and highly infectious strains of the influenza A and influenza B viruses cause millions of cases of severe complications in elderly people, children, and patients with immune diseases each year. Immunoglobulin A (IgA), which is an active component of humoral immunity, can prevent the spread of the virus in the upper respiratory tract. The preparation and study of the properties of recombinant virus-specific IgA could be an important approach to finding new means of preventing and treating influenza. Based on CHO DG44 cells, we developed stable monoclonal cell lines that produce monomeric and dimeric antibodies FI6-IgA1 and FI6-IgA2m1 to hemagglutinin (HA) of the influenza A virus. When studying the productivity, growth, and stability of the obtained clones, we found that the dimeric form of antibodies of IgA1 isotype is superior to other forms. The dimeric form of IgA antibodies plays a key role in mucosal immunity. Recognizing the prospects of using dimeric IgA as prophylactic and therapeutic mucosal drugs for viral infections, we studied their virus-neutralizing and antiviral activities on MDCK cell culture and compared them with the antibodies of the IgG1 isotype. This study presents the data on antiviral and virus-neutralizing activities of the FI6-IgA1 dimers to seasonal and highly infectious strains of influenza A virus.

Influence of media composition on recombinant monoclonal IgA1 glycosylation analysed by lectin-based protein microarray and MALDI-MS

“…We used stable monoclonal cell line producing recombinant dimeric IgA1 antibodies against hemagglutinin of influenza A virus (Argentova et al, 2017). Cell lines cultured in Iscove's Modified Dulbecco's Medium, IMDM (PanEko, Russia) supplemented with L-glutamine (Pa-nEko, Russia) or succinic acid (Komponent-Reaktiv, Russia)/asparagine (Sigma, USA) (in different experiments), 0.1 % Pluronic F68 (Gibco, USA), and antibiotic-antimycotic solution (Gibco, USA) in a CO 2 incubator at 37°C with 96 % humidity in an atmosphere of 8 % CO 2 .…”

Coronavirus [COVID-19] and IgA Deficiency: Mini-Review Article

“…IgA can prevent the spread of the virus, but after the beginning of the disease, the level of IgA decreased [21,22]. On the one hand, The Concentration of mucus IgA is higher than the mucus IgG in tracheal and bronchial mucus which may work on the surface and protect against infection of the PR8 virus.…”